Global Triptorelin Market
Global Triptorelin Market

Triptorelin Comprehensive Study by Type (Triptorelin Pamoate, Triptorelin Acetate, Triptorelin Embonate), Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer, Central Precocious Puberty), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Players and Region - Global Market Outlook to 2025

Triptorelin Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Oct 2020 Edition 232 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Triptorelin Market Scope
Triptorelin is a synthetic decapeptide agonist analog of the luteinizing hormone releasing hormone (LHRH). Available is various form such as, solution, injection, powder indicated for the palliative treatment of advanced prostate cancer. Furthermore, the triptorelin is also used for other indications such as treatment of uterine fibroids, endometriosis, and prior to the surgery or when surgery is not deemed appropriate, as well as early onset puberty and female infertility. Huge investment in research and development activities and favorable government regulations for cancer therapeutics has enhanced the development of drugs. These aspects are the major drivers which are stimulating the growth of the very market.

The Triptorelin market study is segmented by Type (Triptorelin Pamoate, Triptorelin Acetate and Triptorelin Embonate), by Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer and Central Precocious Puberty) and major geographies with country level break-up.

The increasing number of prosthetic cancer patients increasing demand for different drugs in the market. The new drug discovery takes time as well as cost which only possible for top MNCs. The drugs effective, as well as cost-efficient aspects, are more appreciated in the market. The top companies are from the United States who are leading in the market. Mergers and acquisitions are also options for firms to rule the market. Research Analyst at AMA estimates that Global Players will contribute to the maximum growth of Global Triptorelin market throughout the predicted period.

Ipsen (France), Bachem Holding AG (Switzerland), Ferring Pharmaceuticals Pvt Ltd. (Switzerland), Chengdu Tiantaishan Pharmaceutical Co., Ltd. (China), Tecnofarma (Chile), Dr. Reddy’s Laboratories Ltd. (India), Teva Pharmaceutical Industries Ltd. (Isreal), Debiopharm Group (Switzerland) and Arbor Pharmaceuticals, LLC (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Triptorelin market by Type, Application and Region.

On the basis of geography, the market of Triptorelin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Growing Clinical Research Studies for New Application of Triptorelin

Market Drivers
  • Incensing Prevalence of Prostate Cancer Worldwide
  • Rise in Cancer Awareness & Availability of Drugs

Opportunities
  • Increasing Research and Development Activities Focused on Triptorelin Application
  • Rising Purchasing Power of Developing Countries

Restraints
  • Side Effects such as Worsening Mental Problems or Seizures, Allergic Reaction, Bone Pain, etc.

Challenges
  • Long Process for Development and High Cost, Expensive Procedure


Key Target Audience
Triptorelin Manufacturers, Hospital and Diagnostic Centers, Distributors/Suppliers/Wholesalers, Government Sector, Research Firms, Clinical Trial Centres and Downstream Vendors

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Triptorelin Pamoate
  • Triptorelin Acetate
  • Triptorelin Embonate
By Application
  • Prostate Cancer
  • Radical Prostatectomy
  • Endometriosis
  • Salivary Gland Cancer
  • Central Precocious Puberty
By End User
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Incensing Prevalence of Prostate Cancer Worldwide
      • 3.2.2. Rise in Cancer Awareness & Availability of Drugs
    • 3.3. Market Challenges
      • 3.3.1. Long Process for Development and High Cost, Expensive Procedure
    • 3.4. Market Trends
      • 3.4.1. Growing Clinical Research Studies for New Application of Triptorelin
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Triptorelin, by Type, Application, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Triptorelin (Value)
      • 5.2.1. Global Triptorelin by: Type (Value)
        • 5.2.1.1. Triptorelin Pamoate
        • 5.2.1.2. Triptorelin Acetate
        • 5.2.1.3. Triptorelin Embonate
      • 5.2.2. Global Triptorelin by: Application (Value)
        • 5.2.2.1. Prostate Cancer
        • 5.2.2.2. Radical Prostatectomy
        • 5.2.2.3. Endometriosis
        • 5.2.2.4. Salivary Gland Cancer
        • 5.2.2.5. Central Precocious Puberty
      • 5.2.3. Global Triptorelin by: End User (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Retail Pharmacy
        • 5.2.3.3. Online Pharmacy
      • 5.2.4. Global Triptorelin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Triptorelin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ipsen (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bachem Holding AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ferring Pharmaceuticals Pvt Ltd. (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Chengdu Tiantaishan Pharmaceutical Co., Ltd. (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Tecnofarma (Chile)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dr. Reddy’s Laboratories Ltd. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd. (Isreal)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Debiopharm Group (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Arbor Pharmaceuticals, LLC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Triptorelin Sale, by Type, Application, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Triptorelin (Value)
      • 7.2.1. Global Triptorelin by: Type (Value)
        • 7.2.1.1. Triptorelin Pamoate
        • 7.2.1.2. Triptorelin Acetate
        • 7.2.1.3. Triptorelin Embonate
      • 7.2.2. Global Triptorelin by: Application (Value)
        • 7.2.2.1. Prostate Cancer
        • 7.2.2.2. Radical Prostatectomy
        • 7.2.2.3. Endometriosis
        • 7.2.2.4. Salivary Gland Cancer
        • 7.2.2.5. Central Precocious Puberty
      • 7.2.3. Global Triptorelin by: End User (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Retail Pharmacy
        • 7.2.3.3. Online Pharmacy
      • 7.2.4. Global Triptorelin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Triptorelin: by Type(USD Million)
  • Table 2. Triptorelin Triptorelin Pamoate , by Region USD Million (2014-2019)
  • Table 3. Triptorelin Triptorelin Acetate , by Region USD Million (2014-2019)
  • Table 4. Triptorelin Triptorelin Embonate , by Region USD Million (2014-2019)
  • Table 5. Triptorelin: by Application(USD Million)
  • Table 6. Triptorelin Prostate Cancer , by Region USD Million (2014-2019)
  • Table 7. Triptorelin Radical Prostatectomy , by Region USD Million (2014-2019)
  • Table 8. Triptorelin Endometriosis , by Region USD Million (2014-2019)
  • Table 9. Triptorelin Salivary Gland Cancer , by Region USD Million (2014-2019)
  • Table 10. Triptorelin Central Precocious Puberty , by Region USD Million (2014-2019)
  • Table 11. Triptorelin: by End User(USD Million)
  • Table 12. Triptorelin Hospital Pharmacy , by Region USD Million (2014-2019)
  • Table 13. Triptorelin Retail Pharmacy , by Region USD Million (2014-2019)
  • Table 14. Triptorelin Online Pharmacy , by Region USD Million (2014-2019)
  • Table 15. South America Triptorelin, by Country USD Million (2014-2019)
  • Table 16. South America Triptorelin, by Type USD Million (2014-2019)
  • Table 17. South America Triptorelin, by Application USD Million (2014-2019)
  • Table 18. South America Triptorelin, by End User USD Million (2014-2019)
  • Table 19. Brazil Triptorelin, by Type USD Million (2014-2019)
  • Table 20. Brazil Triptorelin, by Application USD Million (2014-2019)
  • Table 21. Brazil Triptorelin, by End User USD Million (2014-2019)
  • Table 22. Argentina Triptorelin, by Type USD Million (2014-2019)
  • Table 23. Argentina Triptorelin, by Application USD Million (2014-2019)
  • Table 24. Argentina Triptorelin, by End User USD Million (2014-2019)
  • Table 25. Rest of South America Triptorelin, by Type USD Million (2014-2019)
  • Table 26. Rest of South America Triptorelin, by Application USD Million (2014-2019)
  • Table 27. Rest of South America Triptorelin, by End User USD Million (2014-2019)
  • Table 28. Asia Pacific Triptorelin, by Country USD Million (2014-2019)
  • Table 29. Asia Pacific Triptorelin, by Type USD Million (2014-2019)
  • Table 30. Asia Pacific Triptorelin, by Application USD Million (2014-2019)
  • Table 31. Asia Pacific Triptorelin, by End User USD Million (2014-2019)
  • Table 32. China Triptorelin, by Type USD Million (2014-2019)
  • Table 33. China Triptorelin, by Application USD Million (2014-2019)
  • Table 34. China Triptorelin, by End User USD Million (2014-2019)
  • Table 35. Japan Triptorelin, by Type USD Million (2014-2019)
  • Table 36. Japan Triptorelin, by Application USD Million (2014-2019)
  • Table 37. Japan Triptorelin, by End User USD Million (2014-2019)
  • Table 38. India Triptorelin, by Type USD Million (2014-2019)
  • Table 39. India Triptorelin, by Application USD Million (2014-2019)
  • Table 40. India Triptorelin, by End User USD Million (2014-2019)
  • Table 41. South Korea Triptorelin, by Type USD Million (2014-2019)
  • Table 42. South Korea Triptorelin, by Application USD Million (2014-2019)
  • Table 43. South Korea Triptorelin, by End User USD Million (2014-2019)
  • Table 44. Taiwan Triptorelin, by Type USD Million (2014-2019)
  • Table 45. Taiwan Triptorelin, by Application USD Million (2014-2019)
  • Table 46. Taiwan Triptorelin, by End User USD Million (2014-2019)
  • Table 47. Australia Triptorelin, by Type USD Million (2014-2019)
  • Table 48. Australia Triptorelin, by Application USD Million (2014-2019)
  • Table 49. Australia Triptorelin, by End User USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Triptorelin, by Type USD Million (2014-2019)
  • Table 51. Rest of Asia-Pacific Triptorelin, by Application USD Million (2014-2019)
  • Table 52. Rest of Asia-Pacific Triptorelin, by End User USD Million (2014-2019)
  • Table 53. Europe Triptorelin, by Country USD Million (2014-2019)
  • Table 54. Europe Triptorelin, by Type USD Million (2014-2019)
  • Table 55. Europe Triptorelin, by Application USD Million (2014-2019)
  • Table 56. Europe Triptorelin, by End User USD Million (2014-2019)
  • Table 57. Germany Triptorelin, by Type USD Million (2014-2019)
  • Table 58. Germany Triptorelin, by Application USD Million (2014-2019)
  • Table 59. Germany Triptorelin, by End User USD Million (2014-2019)
  • Table 60. France Triptorelin, by Type USD Million (2014-2019)
  • Table 61. France Triptorelin, by Application USD Million (2014-2019)
  • Table 62. France Triptorelin, by End User USD Million (2014-2019)
  • Table 63. Italy Triptorelin, by Type USD Million (2014-2019)
  • Table 64. Italy Triptorelin, by Application USD Million (2014-2019)
  • Table 65. Italy Triptorelin, by End User USD Million (2014-2019)
  • Table 66. United Kingdom Triptorelin, by Type USD Million (2014-2019)
  • Table 67. United Kingdom Triptorelin, by Application USD Million (2014-2019)
  • Table 68. United Kingdom Triptorelin, by End User USD Million (2014-2019)
  • Table 69. Netherlands Triptorelin, by Type USD Million (2014-2019)
  • Table 70. Netherlands Triptorelin, by Application USD Million (2014-2019)
  • Table 71. Netherlands Triptorelin, by End User USD Million (2014-2019)
  • Table 72. Rest of Europe Triptorelin, by Type USD Million (2014-2019)
  • Table 73. Rest of Europe Triptorelin, by Application USD Million (2014-2019)
  • Table 74. Rest of Europe Triptorelin, by End User USD Million (2014-2019)
  • Table 75. MEA Triptorelin, by Country USD Million (2014-2019)
  • Table 76. MEA Triptorelin, by Type USD Million (2014-2019)
  • Table 77. MEA Triptorelin, by Application USD Million (2014-2019)
  • Table 78. MEA Triptorelin, by End User USD Million (2014-2019)
  • Table 79. Middle East Triptorelin, by Type USD Million (2014-2019)
  • Table 80. Middle East Triptorelin, by Application USD Million (2014-2019)
  • Table 81. Middle East Triptorelin, by End User USD Million (2014-2019)
  • Table 82. Africa Triptorelin, by Type USD Million (2014-2019)
  • Table 83. Africa Triptorelin, by Application USD Million (2014-2019)
  • Table 84. Africa Triptorelin, by End User USD Million (2014-2019)
  • Table 85. North America Triptorelin, by Country USD Million (2014-2019)
  • Table 86. North America Triptorelin, by Type USD Million (2014-2019)
  • Table 87. North America Triptorelin, by Application USD Million (2014-2019)
  • Table 88. North America Triptorelin, by End User USD Million (2014-2019)
  • Table 89. United States Triptorelin, by Type USD Million (2014-2019)
  • Table 90. United States Triptorelin, by Application USD Million (2014-2019)
  • Table 91. United States Triptorelin, by End User USD Million (2014-2019)
  • Table 92. Canada Triptorelin, by Type USD Million (2014-2019)
  • Table 93. Canada Triptorelin, by Application USD Million (2014-2019)
  • Table 94. Canada Triptorelin, by End User USD Million (2014-2019)
  • Table 95. Mexico Triptorelin, by Type USD Million (2014-2019)
  • Table 96. Mexico Triptorelin, by Application USD Million (2014-2019)
  • Table 97. Mexico Triptorelin, by End User USD Million (2014-2019)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Triptorelin: by Type(USD Million)
  • Table 108. Triptorelin Triptorelin Pamoate , by Region USD Million (2020-2025)
  • Table 109. Triptorelin Triptorelin Acetate , by Region USD Million (2020-2025)
  • Table 110. Triptorelin Triptorelin Embonate , by Region USD Million (2020-2025)
  • Table 111. Triptorelin: by Application(USD Million)
  • Table 112. Triptorelin Prostate Cancer , by Region USD Million (2020-2025)
  • Table 113. Triptorelin Radical Prostatectomy , by Region USD Million (2020-2025)
  • Table 114. Triptorelin Endometriosis , by Region USD Million (2020-2025)
  • Table 115. Triptorelin Salivary Gland Cancer , by Region USD Million (2020-2025)
  • Table 116. Triptorelin Central Precocious Puberty , by Region USD Million (2020-2025)
  • Table 117. Triptorelin: by End User(USD Million)
  • Table 118. Triptorelin Hospital Pharmacy , by Region USD Million (2020-2025)
  • Table 119. Triptorelin Retail Pharmacy , by Region USD Million (2020-2025)
  • Table 120. Triptorelin Online Pharmacy , by Region USD Million (2020-2025)
  • Table 121. South America Triptorelin, by Country USD Million (2020-2025)
  • Table 122. South America Triptorelin, by Type USD Million (2020-2025)
  • Table 123. South America Triptorelin, by Application USD Million (2020-2025)
  • Table 124. South America Triptorelin, by End User USD Million (2020-2025)
  • Table 125. Brazil Triptorelin, by Type USD Million (2020-2025)
  • Table 126. Brazil Triptorelin, by Application USD Million (2020-2025)
  • Table 127. Brazil Triptorelin, by End User USD Million (2020-2025)
  • Table 128. Argentina Triptorelin, by Type USD Million (2020-2025)
  • Table 129. Argentina Triptorelin, by Application USD Million (2020-2025)
  • Table 130. Argentina Triptorelin, by End User USD Million (2020-2025)
  • Table 131. Rest of South America Triptorelin, by Type USD Million (2020-2025)
  • Table 132. Rest of South America Triptorelin, by Application USD Million (2020-2025)
  • Table 133. Rest of South America Triptorelin, by End User USD Million (2020-2025)
  • Table 134. Asia Pacific Triptorelin, by Country USD Million (2020-2025)
  • Table 135. Asia Pacific Triptorelin, by Type USD Million (2020-2025)
  • Table 136. Asia Pacific Triptorelin, by Application USD Million (2020-2025)
  • Table 137. Asia Pacific Triptorelin, by End User USD Million (2020-2025)
  • Table 138. China Triptorelin, by Type USD Million (2020-2025)
  • Table 139. China Triptorelin, by Application USD Million (2020-2025)
  • Table 140. China Triptorelin, by End User USD Million (2020-2025)
  • Table 141. Japan Triptorelin, by Type USD Million (2020-2025)
  • Table 142. Japan Triptorelin, by Application USD Million (2020-2025)
  • Table 143. Japan Triptorelin, by End User USD Million (2020-2025)
  • Table 144. India Triptorelin, by Type USD Million (2020-2025)
  • Table 145. India Triptorelin, by Application USD Million (2020-2025)
  • Table 146. India Triptorelin, by End User USD Million (2020-2025)
  • Table 147. South Korea Triptorelin, by Type USD Million (2020-2025)
  • Table 148. South Korea Triptorelin, by Application USD Million (2020-2025)
  • Table 149. South Korea Triptorelin, by End User USD Million (2020-2025)
  • Table 150. Taiwan Triptorelin, by Type USD Million (2020-2025)
  • Table 151. Taiwan Triptorelin, by Application USD Million (2020-2025)
  • Table 152. Taiwan Triptorelin, by End User USD Million (2020-2025)
  • Table 153. Australia Triptorelin, by Type USD Million (2020-2025)
  • Table 154. Australia Triptorelin, by Application USD Million (2020-2025)
  • Table 155. Australia Triptorelin, by End User USD Million (2020-2025)
  • Table 156. Rest of Asia-Pacific Triptorelin, by Type USD Million (2020-2025)
  • Table 157. Rest of Asia-Pacific Triptorelin, by Application USD Million (2020-2025)
  • Table 158. Rest of Asia-Pacific Triptorelin, by End User USD Million (2020-2025)
  • Table 159. Europe Triptorelin, by Country USD Million (2020-2025)
  • Table 160. Europe Triptorelin, by Type USD Million (2020-2025)
  • Table 161. Europe Triptorelin, by Application USD Million (2020-2025)
  • Table 162. Europe Triptorelin, by End User USD Million (2020-2025)
  • Table 163. Germany Triptorelin, by Type USD Million (2020-2025)
  • Table 164. Germany Triptorelin, by Application USD Million (2020-2025)
  • Table 165. Germany Triptorelin, by End User USD Million (2020-2025)
  • Table 166. France Triptorelin, by Type USD Million (2020-2025)
  • Table 167. France Triptorelin, by Application USD Million (2020-2025)
  • Table 168. France Triptorelin, by End User USD Million (2020-2025)
  • Table 169. Italy Triptorelin, by Type USD Million (2020-2025)
  • Table 170. Italy Triptorelin, by Application USD Million (2020-2025)
  • Table 171. Italy Triptorelin, by End User USD Million (2020-2025)
  • Table 172. United Kingdom Triptorelin, by Type USD Million (2020-2025)
  • Table 173. United Kingdom Triptorelin, by Application USD Million (2020-2025)
  • Table 174. United Kingdom Triptorelin, by End User USD Million (2020-2025)
  • Table 175. Netherlands Triptorelin, by Type USD Million (2020-2025)
  • Table 176. Netherlands Triptorelin, by Application USD Million (2020-2025)
  • Table 177. Netherlands Triptorelin, by End User USD Million (2020-2025)
  • Table 178. Rest of Europe Triptorelin, by Type USD Million (2020-2025)
  • Table 179. Rest of Europe Triptorelin, by Application USD Million (2020-2025)
  • Table 180. Rest of Europe Triptorelin, by End User USD Million (2020-2025)
  • Table 181. MEA Triptorelin, by Country USD Million (2020-2025)
  • Table 182. MEA Triptorelin, by Type USD Million (2020-2025)
  • Table 183. MEA Triptorelin, by Application USD Million (2020-2025)
  • Table 184. MEA Triptorelin, by End User USD Million (2020-2025)
  • Table 185. Middle East Triptorelin, by Type USD Million (2020-2025)
  • Table 186. Middle East Triptorelin, by Application USD Million (2020-2025)
  • Table 187. Middle East Triptorelin, by End User USD Million (2020-2025)
  • Table 188. Africa Triptorelin, by Type USD Million (2020-2025)
  • Table 189. Africa Triptorelin, by Application USD Million (2020-2025)
  • Table 190. Africa Triptorelin, by End User USD Million (2020-2025)
  • Table 191. North America Triptorelin, by Country USD Million (2020-2025)
  • Table 192. North America Triptorelin, by Type USD Million (2020-2025)
  • Table 193. North America Triptorelin, by Application USD Million (2020-2025)
  • Table 194. North America Triptorelin, by End User USD Million (2020-2025)
  • Table 195. United States Triptorelin, by Type USD Million (2020-2025)
  • Table 196. United States Triptorelin, by Application USD Million (2020-2025)
  • Table 197. United States Triptorelin, by End User USD Million (2020-2025)
  • Table 198. Canada Triptorelin, by Type USD Million (2020-2025)
  • Table 199. Canada Triptorelin, by Application USD Million (2020-2025)
  • Table 200. Canada Triptorelin, by End User USD Million (2020-2025)
  • Table 201. Mexico Triptorelin, by Type USD Million (2020-2025)
  • Table 202. Mexico Triptorelin, by Application USD Million (2020-2025)
  • Table 203. Mexico Triptorelin, by End User USD Million (2020-2025)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Triptorelin: by Type USD Million (2014-2019)
  • Figure 5. Global Triptorelin: by Application USD Million (2014-2019)
  • Figure 6. Global Triptorelin: by End User USD Million (2014-2019)
  • Figure 7. South America Triptorelin Share (%), by Country
  • Figure 8. Asia Pacific Triptorelin Share (%), by Country
  • Figure 9. Europe Triptorelin Share (%), by Country
  • Figure 10. MEA Triptorelin Share (%), by Country
  • Figure 11. North America Triptorelin Share (%), by Country
  • Figure 12. Global Triptorelin share by Players 2019 (%)
  • Figure 13. Global Triptorelin share by Players (Top 3) 2019(%)
  • Figure 14. Global Triptorelin share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Ipsen (France) Revenue, Net Income and Gross profit
  • Figure 17. Ipsen (France) Revenue: by Geography 2019
  • Figure 18. Bachem Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Bachem Holding AG (Switzerland) Revenue: by Geography 2019
  • Figure 20. Ferring Pharmaceuticals Pvt Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Ferring Pharmaceuticals Pvt Ltd. (Switzerland) Revenue: by Geography 2019
  • Figure 22. Chengdu Tiantaishan Pharmaceutical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 23. Chengdu Tiantaishan Pharmaceutical Co., Ltd. (China) Revenue: by Geography 2019
  • Figure 24. Tecnofarma (Chile) Revenue, Net Income and Gross profit
  • Figure 25. Tecnofarma (Chile) Revenue: by Geography 2019
  • Figure 26. Dr. Reddy’s Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 27. Dr. Reddy’s Laboratories Ltd. (India) Revenue: by Geography 2019
  • Figure 28. Teva Pharmaceutical Industries Ltd. (Isreal) Revenue, Net Income and Gross profit
  • Figure 29. Teva Pharmaceutical Industries Ltd. (Isreal) Revenue: by Geography 2019
  • Figure 30. Debiopharm Group (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Debiopharm Group (Switzerland) Revenue: by Geography 2019
  • Figure 32. Arbor Pharmaceuticals, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 33. Arbor Pharmaceuticals, LLC (United States) Revenue: by Geography 2019
  • Figure 34. Global Triptorelin: by Type USD Million (2020-2025)
  • Figure 35. Global Triptorelin: by Application USD Million (2020-2025)
  • Figure 36. Global Triptorelin: by End User USD Million (2020-2025)
  • Figure 37. South America Triptorelin Share (%), by Country
  • Figure 38. Asia Pacific Triptorelin Share (%), by Country
  • Figure 39. Europe Triptorelin Share (%), by Country
  • Figure 40. MEA Triptorelin Share (%), by Country
  • Figure 41. North America Triptorelin Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Ipsen (France)
  • Bachem Holding AG (Switzerland)
  • Ferring Pharmaceuticals Pvt Ltd. (Switzerland)
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd. (China)
  • Tecnofarma (Chile)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Teva Pharmaceutical Industries Ltd. (Isreal)
  • Debiopharm Group (Switzerland)
  • Arbor Pharmaceuticals, LLC (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation